$Phase II Trial of Tremelimumab (CP-675,206) in Patients with Advanced Refractory or Relapsed Melanoma$
QR Code

Phase II Trial of Tremelimumab (CP-675,206) in Patients with Advanced Refractory or Relapsed Melanoma

Purpose: This phase II study assessed the antitumor activity of tremelimumab, a fully human, anti–CTL-associated antigen 4 monoclonal antibody, in patients with melanoma. Experimental Design: Patients with refractory/relapsed melanoma received 15 mg/kg tremelimumab every 90 days. After 4 doses, pati...

Full description

Saved in:

Bibliographic Details
Published in:	Clinical cancer research Vol. 16; no. 3; pp. 1042 - 1048
Main Authors:	KIRKWOOD, John M, LORIGAN, Paul, HERSEY, Peter, HAUSCHILD, Axel, ROBERT, Caroline, MCDERMOTT, David, MARSHALL, Margaret A, GOMEZ-NAVARRO, Jesus, LIANG, Jane Q, BULANHAGUI, Cecile A
Format:	Journal Article
Language:	English
Published:	Philadelphia, PA American Association for Cancer Research 01-02-2010
Subjects:	Adolescent Adult Aged Aged, 80 and over anti-CTLA4 monoclonal antibody Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal - therapeutic use Antineoplastic agents Biological and medical sciences Dermatology Drug Administration Schedule Drug Resistance, Neoplasm Female Humans Male Medical sciences melanoma Melanoma - drug therapy Melanoma - pathology Middle Aged Pharmacology. Drug treatments Recurrence Skin Neoplasms - drug therapy Skin Neoplasms - pathology Tumors of the skin and soft tissue. Premalignant lesions Human Tremelimumab Relapse Treatment resistance Phase II trial Malignant melanoma Patient Advanced stage Malignant tumor Cancer
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!